Analysis of Ubiquitin-Specific Protease 9X Expression in Pancreatic Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 ZHANGPeng-bo , DINGWei-chao , ZHANGXiu-zhong , ZHANGChong ,  RENZe-qiang

Department of General Surgery, Affiliated Hospital of Xuzhou Medical College, Xuzhou 221002, Jiangsu Province, China;

Corresponding author：

RENZe-qiang, Email: rzq0805@189.cn

Keywords：

Pancreatic cancer; Ubiquitin-specific protease 9x; Immunohistochemical method; Prognosis

DOI：

10.7507/1007-9424.20150157

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the expression of ubiquitin-specific protease 9X (USP9X) in pancreatic cancer, and to evaluate the correlation of USP9X with the survival of patients with pancreatic cancer. Method The expression of USP9X was detected in 55 pieces of surgically resected primary pancreatic cancer tissues and adjacent nontumorous pancreatic tissues by streptavidin-perosidase immunohistochemical method. Results The rate of USP9X high expression in the 55 pieces of the primary pancreatic cancer tissues was 58.2% (32/55), which in the adjacent nontumorous pancreatic tissues was zero. The expression of USP9X was not correlated with the gender, age, tumor position, or tumor size (P > 0.05), while which was significantly correlated with the differentiation degree, lymph node metastasis, or TNM stage (P < 0.05). By using Cox proportional hazard model, the multivariable analysis revealed that the differentiation degree, lymph node metastasis, and USP9X expression were the independent risk factors. Survival of the patient with USP9X high expression was significantly shorter than that with USP9X low expression (P < 0.05), and there was the same result in the patients with stageⅡ, with lymph node negative, or intermediate differentiation degree (P < 0.05). Conclusion The results indicate that USP9X might play an important role in the pathogenesis and prognosis of pancreatic cancer.

Citation： ZHANGPeng-bo, DINGWei-chao, ZHANGXiu-zhong, ZHANGChong, RENZe-qiang. Analysis of Ubiquitin-Specific Protease 9X Expression in Pancreatic Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(5): 601-604. doi: 10.7507/1007-9424.20150157 Copy

1.	刘海林, 王磊.胰腺癌早期诊断与治疗的研究进展.世界华人消化杂志, 2009, 17(34):3475-3479.
2.	丁伟超, 张蓬波, 张秀忠, 等.胰腺癌组织中survivin的表达及与预后的关系.中国普通外科杂志, 2014, 23(3):329-332.
3.	杨波, 谢丛华.泛素特异性蛋白酶9X与肿瘤.国际肿瘤学杂志, 2011, 38(12):900-902.
4.	成东华.胰腺癌的TNM分期.中国实用外科杂志, 2004, 24(5):67.
5.	Peng J, Hu Q, Liu WP, et al. USP9X expression correlates with tumor progression and poor prognosis in esophageal squamous cell carcinoma. Diagn Pathol, 2013, 8(1):177-185.
6.	王素霞, 刘媛, 吴慧娟, 等.去泛素化酶的研究及其进展.临床与实验病理学杂志, 2008, 24(6):734-737.
7.	戴陈新, 袁健, 郑亚新.去泛素化酶与肿瘤发生及发展关系的研究进展.中国癌症杂志, 2013, 23(7):547-550.
8.	Crosas B. Deubiquitinating enzyme inhibitors and their potential in cancer therapy. Curr Cancer Drug Targets, 2014, 14(6):506-516.
9.	Fraile JM, Quesada V, Rodriguez D, et al. Deubiquitinases in cancer:new functions and therapeutic options. Oncogene, 2012, 31(19):2373-2388.
10.	姚闪, 陈松, 叶茂.去泛素化酶USP7在细胞中的功能作用及其研究进展.激光生物学报, 2014, 23(1):9-15.
11.	特日格勒, 孙文靖, 于旸, 等.泛素特异性蛋白酶与肿瘤关系的研究.国际遗传学杂志, 2013, 36(4):162-167.
12.	Burger AM, Seth AK. The ubiquitin-mediated protein degradation pathway in cancer:therapeutic implications. Eur J Cancer, 2004, 40(15):2217-2229.
13.	Pal A, Young MA, Donato NJ. Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer. Cancer Res, 2014, 74(18):4955-4966.
14.	Reyes-Turcu FE, Wilkinson KD. Polyubiquitin binding and disassembly by deubiquitinating enzymes. Chem Rev, 2009, 109(4):1495-1508.
15.	Agrawal P, Chen YT, Schilling B, et al. Ubiquitin-specific peptidase 9, X-linked (USP9X) modulates activity of mammalian target of rapamycin (mTOR). J Biol Chem, 2012, 287(25):21164-21175.
16.	Populo H, Lopes JM, Soares P. The mTOR signalling pathway in human cancer. Int J Mol Sci, 2012, 13(2):1886-1918.
17.	Schwickart M, Huang X, Lill JR, et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature, 2010, 463(7277):103-107.
18.	Nagai H, Noguchi T, Homma K, et al. Ubiquitin-like sequence in ASKl plays critical roles in the recognition and stabilization by USP9X and oxidative stress-induced cell death. Mol Cell, 2009, 36(5):805-818.
19.	魏本尊, 李捷, 沈超, 等.去泛素化酶USP9X在etoposide促结肠癌细胞SW620凋亡中的作用研究.中国现代普通外科进展, 2014, 17(1):8-11, 68.
20.	Trivigno D, Essmann F, Huber SM, et al. Deubiquitinase USP9x confers radioresistance through stabilization of Mcl-1. Neoplasia, 2012, 14(10):893-904.
21.	Harris DR, Mims A, Bunz F. Genetic disruption of USP9X sensitizes colorectal cancer cells to 5-fluorouracil. Cancer Biol Ther, 2012, 13(13):1319-1324.
22.	胡静, 谢丛华.去泛素化酶USP9X对胶质瘤细胞U251放射敏感性的影响.武汉大学学报:医学版, 2013, 34(2):213-216.
23.	许娟娟, 刘诗, 易粹琼.胰腺癌的研究进展.临床消化病杂志, 2012, 24(2):117-120.
24.	张建宇, 杜云翔, 刘永新, 等.介入化疗联合伽玛刀治疗胰腺癌27例临床分析.徐州医学院学报, 2013, 33(7):473-475.
25.	姚汝铖, 郑军, 邢荣春.微小RNA在胰腺癌中的研究进展.中国普外基础与临床杂志, 2012, 19(8):911-915.

1. 刘海林, 王磊.胰腺癌早期诊断与治疗的研究进展.世界华人消化杂志, 2009, 17(34):3475-3479.
2. 丁伟超, 张蓬波, 张秀忠, 等.胰腺癌组织中survivin的表达及与预后的关系.中国普通外科杂志, 2014, 23(3):329-332.
3. 杨波, 谢丛华.泛素特异性蛋白酶9X与肿瘤.国际肿瘤学杂志, 2011, 38(12):900-902.
4. 成东华.胰腺癌的TNM分期.中国实用外科杂志, 2004, 24(5):67.
5. Peng J, Hu Q, Liu WP, et al. USP9X expression correlates with tumor progression and poor prognosis in esophageal squamous cell carcinoma. Diagn Pathol, 2013, 8(1):177-185.
6. 王素霞, 刘媛, 吴慧娟, 等.去泛素化酶的研究及其进展.临床与实验病理学杂志, 2008, 24(6):734-737.
7. 戴陈新, 袁健, 郑亚新.去泛素化酶与肿瘤发生及发展关系的研究进展.中国癌症杂志, 2013, 23(7):547-550.
8. Crosas B. Deubiquitinating enzyme inhibitors and their potential in cancer therapy. Curr Cancer Drug Targets, 2014, 14(6):506-516.
9. Fraile JM, Quesada V, Rodriguez D, et al. Deubiquitinases in cancer:new functions and therapeutic options. Oncogene, 2012, 31(19):2373-2388.
10. 姚闪, 陈松, 叶茂.去泛素化酶USP7在细胞中的功能作用及其研究进展.激光生物学报, 2014, 23(1):9-15.
11. 特日格勒, 孙文靖, 于旸, 等.泛素特异性蛋白酶与肿瘤关系的研究.国际遗传学杂志, 2013, 36(4):162-167.
12. Burger AM, Seth AK. The ubiquitin-mediated protein degradation pathway in cancer:therapeutic implications. Eur J Cancer, 2004, 40(15):2217-2229.
13. Pal A, Young MA, Donato NJ. Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer. Cancer Res, 2014, 74(18):4955-4966.
14. Reyes-Turcu FE, Wilkinson KD. Polyubiquitin binding and disassembly by deubiquitinating enzymes. Chem Rev, 2009, 109(4):1495-1508.
15. Agrawal P, Chen YT, Schilling B, et al. Ubiquitin-specific peptidase 9, X-linked (USP9X) modulates activity of mammalian target of rapamycin (mTOR). J Biol Chem, 2012, 287(25):21164-21175.
16. Populo H, Lopes JM, Soares P. The mTOR signalling pathway in human cancer. Int J Mol Sci, 2012, 13(2):1886-1918.
17. Schwickart M, Huang X, Lill JR, et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature, 2010, 463(7277):103-107.
18. Nagai H, Noguchi T, Homma K, et al. Ubiquitin-like sequence in ASKl plays critical roles in the recognition and stabilization by USP9X and oxidative stress-induced cell death. Mol Cell, 2009, 36(5):805-818.
19. 魏本尊, 李捷, 沈超, 等.去泛素化酶USP9X在etoposide促结肠癌细胞SW620凋亡中的作用研究.中国现代普通外科进展, 2014, 17(1):8-11, 68.
20. Trivigno D, Essmann F, Huber SM, et al. Deubiquitinase USP9x confers radioresistance through stabilization of Mcl-1. Neoplasia, 2012, 14(10):893-904.
21. Harris DR, Mims A, Bunz F. Genetic disruption of USP9X sensitizes colorectal cancer cells to 5-fluorouracil. Cancer Biol Ther, 2012, 13(13):1319-1324.
22. 胡静, 谢丛华.去泛素化酶USP9X对胶质瘤细胞U251放射敏感性的影响.武汉大学学报:医学版, 2013, 34(2):213-216.
23. 许娟娟, 刘诗, 易粹琼.胰腺癌的研究进展.临床消化病杂志, 2012, 24(2):117-120.
24. 张建宇, 杜云翔, 刘永新, 等.介入化疗联合伽玛刀治疗胰腺癌27例临床分析.徐州医学院学报, 2013, 33(7):473-475.
25. 姚汝铖, 郑军, 邢荣春.微小RNA在胰腺癌中的研究进展.中国普外基础与临床杂志, 2012, 19(8):911-915.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Analysis of Ubiquitin-Specific Protease 9X Expression in Pancreatic Cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content